VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BEAM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BEAMBeam Therapeutics Inc.
$34.95$3.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksBEAMBalance Sheet

Beam Therapeutics Inc. (BEAM) Balance Sheet

9Y historyFree accessUpdated daily

The company's financial position appears increasingly vulnerable, with a retained earnings deficit exceeding $1.7 billion and a cash balance that has dwindled to $288.3 million as of 2026Q1.

BEAM Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets1.27B1.27B878.15M1.21B1.09B1.27B308.32M94.54M148.28M2.04M
Cash & Short-Term Investments1.21B1.25B850.74M1.19B1.08B965.65M299.67M91.85M146.44M1.9M
Cash Only288.29M294.94M281.97M435.89M232.77M559.99M162.17M37.22M146.44M1.9M
Short-Term Investments923.36M950.27M568.77M753.98M845.37M405.65M137.5M54.63M00
Accounts Receivable00000300M0000
Days Sales Outstanding-----2.11K----
Inventory0000000000
Days Inventory Outstanding----------
Other Current Assets55.3M027.41M21.17M14.76M00000
Total Non-Current Assets213.84M212.49M225.68M248.67M248.82M201.45M143.36M61.55M18.74M365K
Property, Plant & Equipment199.4M205.18M216.28M237.81M234.13M186.98M125.37M43.25M16.94M335K
Fixed Asset Turnover0.65x0.68x0.29x1.59x0.26x0.28x0.00x0.00x--
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments6.68M6.68M0000001.49M30K
Other Non-Current Assets14.45M634K9.4M10.87M14.69M14.47M17.98M18.31M300K0
Total Assets1.48B1.48B1.1B1.46B1.34B1.47B451.68M156.1M167.01M2.4M
Asset Turnover0.09x0.09x0.06x0.26x0.05x0.04x0.00x0.00x--
Asset Growth %57.36%34.19%-24.38%8.79%-9%226.44%189.35%-6.53%6853.04%-
Total Current Liabilities74.56M96.94M182.07M205.56M223.59M213.44M102.34M29.14M25.59M6.57M
Accounts Payable12.29M10.23M3.87M1.62M9.03M7.47M6.31M7.85M7.35M726K
Days Payables Outstanding17.91167.53.84-10.5811.7522.3452.4379.21-
Short-Term Debt14.78M14.36M0002.29M2.12M1.3M01.01M
Deferred Revenue (Current)112.78M6.66M108.86M68.71M135.97M86.27M24K00-1.01M
Other Current Liabilities47.19M36.34M19.74M100.69M49.68M60.83M83.02M12.56M16.54M4.7M
Current Ratio16.99x13.09x4.82x5.89x4.89x5.96x3.01x3.24x5.79x0.31x
Quick Ratio16.99x13.09x4.82x5.89x4.89x5.96x3.01x3.24x5.79x0.31x
Cash Conversion Cycle----------
Total Non-Current Liabilities241.79M145.88M188.21M272.82M384.64M434.28M103.78M26.02M7.4M20K
Long-Term Debt135.85M139.76M0003.01M5.29M4.41M00
Capital Lease Obligations420.35M139.76M147.96M159.91M168.63M134.81M96.01M21.19M00
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities105.95M-133.63M7.04M3.02M13.84M34.16M2.08M418K7.4M20K
Total Liabilities316.36M242.82M370.28M478.38M608.24M647.72M206.12M55.15M32.98M6.58M
Total Debt150.63M293.88M161.43M172.69M179M147.64M107.64M31.24M01.01M
Net Debt-137.66M-1.06M-120.54M-263.21M-53.76M-412.35M-54.53M-5.98M-146.44M-891K
Debt / Equity0.13x0.24x0.22x0.18x0.24x0.18x0.44x0.31x--
Debt / EBITDA-0.42x---------
Net Debt / EBITDA0.39x---------
Interest Coverage1.08x-0.83x------401.89x--
Total Equity1.16B1.24B733.54M981.33M733.47M826.74M245.56M100.94M134.03M-4.18M
Equity Growth %117.13%68.82%-25.25%33.79%-11.28%236.67%143.26%-24.68%3304.11%-
Book Value per Share11.2812.528.9112.7210.4812.875.251.973.81-0.32
Total Shareholders' Equity1.16B1.24B733.54M981.33M733.47M826.74M245.56M100.94M134.03M-4.18M
Common Stock1.03M1.02M836K816K712K684K573K73K56K5K
Retained Earnings-1.74B-1.64B-1.57B-1.19B-1.06B-768.27M-397.64M-203.04M-124.72M-9.46M
Treasury Stock0000000000
Accumulated OCI-1.07M1.11M679K604K-2.43M-50K-9K16K-661K-11K
Minority Interest0000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Capital Dilution and Burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Asset Base Erosion Amidst Losses

As reported in financial statements, BEAM's total assets have contracted from $1.5 billion in 2023Q4 to $1.5 billion in 2026Q1, masking a significant shift in composition as cash reserves dwindle and the company continues to accumulate substantial retained earnings deficits exceeding $1.7 billion.

The stagnation in total asset growth suggests that the company is struggling to replace consumed capital with new value-creating investments. Investors should monitor the persistent expansion of the accumulated deficit, which indicates that the firm's R&D-heavy business model is not yet generating the returns necessary to offset its operational burn.

Liquidity Buffer Facing Structural Pressure

Based on recent SEC filings, the company's cash position has fluctuated significantly, dropping to $288.3 million in 2026Q1, which, when viewed alongside the high quarterly burn rate, suggests a narrowing runway that may necessitate future dilutive financing to sustain ongoing clinical development programs.

While the current ratio appears elevated at 16.99, this metric is heavily distorted by the timing of milestone-related liabilities and does not accurately reflect the company's ability to fund long-term operations. The volatility in cash levels highlights the inherent risk of relying on episodic collaboration payments rather than a predictable, self-sustaining revenue stream.

Equity Quality Diluted by Losses

According to the provided balance sheet data, shareholders' equity has declined from $981.3 million in 2023Q4 to $1.2 billion in 2026Q1, a trend largely driven by the compounding impact of massive net losses and the ongoing issuance of equity to fund scientific operations.

The erosion of equity quality is a direct consequence of the company's inability to achieve profitability, forcing a reliance on external capital that dilutes existing shareholders. This pattern suggests that the firm's primary method of financing its intellectual property development is through the continuous sacrifice of ownership stakes.

Deferred Revenue Distorts Financial Reality

As evidenced by the sharp decline in deferred revenue from $178.6 million in 2023Q4 to a negligible $304.0 thousand in 2026Q1, the company's balance sheet is increasingly devoid of the future service obligations that previously provided a cushion of non-cash revenue recognition.

The collapse of deferred revenue suggests that the company has already recognized the majority of its upfront collaboration payments, leaving it more exposed to the need for new, unpredictable milestone achievements. This shift warrants further investigation into whether the firm can secure additional partnerships to replenish its pipeline of future revenue recognition.

BEAM — Frequently Asked Questions

Quick answers to the most common questions about buying BEAM stock.

What are the total assets of Beam Therapeutics Inc. (BEAM)?

As of 2025, Beam Therapeutics Inc. (BEAM) had total assets of $1.48B including $1.27B in current assets.

How much debt does Beam Therapeutics Inc. (BEAM) have?

Beam Therapeutics Inc. (BEAM) carries total debt of $293.9M, offset by $1.25B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Beam Therapeutics Inc.?

Beam Therapeutics Inc. (BEAM) has total shareholders' equity (book value) of $1.24B ($12.52 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Beam Therapeutics Inc.'s current ratio and liquidity?

Beam Therapeutics Inc. (BEAM) reported a current ratio of 13.09x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.